Outlook Therapeutics, Inc. (OTLK) completed a Federal Dispute Resolution (FDR) meeting with the U.S. Food and Drug Administration’s Office of New Drugs on April 21, 2026, to discuss its ophthalmic bevacizumab formulation ONS‑5010/LYTENAVA (LYTENAVA). The meeting followed a December 30, 2025 Complete Response Letter that cited a lack of substantial evidence of effectiveness for the product.
During the session, Outlook presented additional clinical data and addressed the FDA’s concerns about the evidence supporting LYTENAVA. The company’s leadership emphasized that the data from the NORSE TWO and NORSE EIGHT studies demonstrate sufficient safety and efficacy to support approval, and that the meeting represents a procedural step toward a formal FDA decision in May 2026.
"We appreciate the opportunity to engage in constructive dialogue with the FDA through the FDR process," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "We believe this meeting represents an important step in advancing our regulatory strategy." Jahr added that the company remains committed to working collaboratively with the agency to establish a clear path forward toward potential U.S. approval.
Outlook’s LYTENAVA has already received marketing authorization in the European Union and the United Kingdom and has begun commercial launch in Germany and the UK. The company maintains a fully domestic, end‑to‑end U.S. manufacturing supply chain for the product. In March 2026, Outlook closed a $5 million public stock offering and an $18.4 million note financing, bringing its market capitalization to approximately $33.27 million and reinforcing its financial position despite a “poor” strength rating of 1/10.
The FDR meeting is a key regulatory milestone that keeps Outlook’s U.S. approval process active. The company expects formal feedback from the FDA in May 2026, and the outcome will determine whether LYTENAVA can become the first FDA‑approved ophthalmic bevacizumab for retinal indications, potentially opening a significant U.S. market for the product.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.